BACKGROUND
Pinpoint Genomics was a diagnostics company in Mountain View, California. They developed a quantitative PCR (Polymerase Chain Reaction) lab-developed test for early-stage non-small cell lung cancer. This test can help doctors identify those early-stage lung cancer patients at high risk for progression to late-stage disease.
OPPORTUNITY
As a small company, Pinpoint needed the expertise of the DNA Ink team to appropriately position their product with potential partners in a complex marketplace.
OUR WORK
To assist the company, we:
- Created a patient-based bottoms-up revenue forecast for the assay.
- Worked with the client to coordinate a data package that clearly outlined the business opportunity in a new market.
- Leveraged long-term contacts in the industry to enable the test to receive appropriate review within large and small diagnostic companies.
- Assisted client in managing the pitch and due diligence process, and term sheet and contract negotiations.
RESULT
Pinpoint Genomics was acquired by Life Technologies. The product, Pervenio Lung DS, a risk stratification test for early-stage lung cancer, was launched two months later. The founders of Pinpoint Genomics have dedicated their lives to finding a cure for lung cancer. It was an honor for the DNA Ink team to be a part of such a meaningful and life-enhancing product. <Press Release>
